GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
41.74
-0.01 (-0.02%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close41.75
Open41.63
Bid40.70 x 4000
Ask0.00 x 1800
Day's Range41.61 - 41.78
52 Week Range34.52 - 42.95
Volume1,439,109
Avg. Volume2,343,955
Market Cap103.903B
Beta0.66
PE Ratio (TTM)75.34
EPS (TTM)0.55
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield2.17 (5.29%)
Ex-Dividend Date2018-05-10
1y Target Est42.13
Trade prices are not sourced from all markets
  • Why GSK just inked a $330M deal with a Roivant subsidiary
    American City Business Journals3 days ago

    Why GSK just inked a $330M deal with a Roivant subsidiary

    GlaxoSmithKline (NYSE: GSK) and Roivant subsidiary Dermavant have inked a deal worth about $330 million. Dermavant, which has a sizable presence at Roivant’s research and development-heavy outpost in Durham, has agreed to purchase the rights to GSK’s drug tapinarof – a treatment under development for psoriasis and atopic dermatitis – and its backup programs for an initial payment of about $200 million and future milestone payment of about $130 million.  “This was the result of a strategic decision to no longer focus on developing assets that are topical and exclusively a dermatology medicine,” a GSK spokeswoman said Thursday in an email. “We have been exploring opportunities to divest or partner such medicines to realize their potential value for patients and, through this process, selected Roivant and Dermavant for tapinarof.” At the end of May, Cheryl MacDiarmid, senior vice president of primary care at GSK, who leads the company’s commercial respiratory business unit in Research Triangle Park, said in an interview that the Triangle is at the center of activity as GSK shifts and broadens its cornerstone respiratory portfolio.

  • $331M deal: GSK sells rights to experimental psoriasis drug
    American City Business Journals3 days ago

    $331M deal: GSK sells rights to experimental psoriasis drug

    The buyer, Roivant subsidiary Dermavant, will make an upfront payment of $199 million to GlaxoSmithKline.

  • Pfizer (PFE) to Reorganize Business Into Three New Units
    Zacks3 days ago

    Pfizer (PFE) to Reorganize Business Into Three New Units

    Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.

  • Benzinga7 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    Biotech stocks held their ground in a holiday-shortened week amid a drought of market-moving catalysts. Looking ahead, the following are catalytic events for biotech investors to watch.  Conferences Fourth ...

  • GlaxoSmithKline Stock’s June Performance
    Market Realist10 days ago

    GlaxoSmithKline Stock’s June Performance

    British multinational pharmaceutical company GlaxoSmithKline (GSK) divides its business into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. As it is a British company, it reports its revenue in British pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since Q1 2017, and analysts’ estimate for Q2 2018.

  • How Novartis’s Valuation Compares
    Market Realist11 days ago

    How Novartis’s Valuation Compares

    Healthcare giant Novartis (NVS) researches, develops, manufactures, and commercializes pharmaceutical products. Novartis surpassed analysts’ revenue and EPS estimates during Q1 2018, with its revenue growing 4% year-over-year to $12.7 billion from $11.5 billion at constant exchange rates. Foreign exchange boosted its revenue by 6%.

  • Analysts’ Estimates and Recommendations for GSK in June
    Market Realist11 days ago

    Analysts’ Estimates and Recommendations for GSK in June

    Analysts expect GlaxoSmithKline (GSK) to report revenue of ~7.1 billion British pounds during the second quarter, a 2.3% fall in year-over-year revenue compared to ~7.3 billion pounds during the second quarter of 2017. The company’s EPS are expected to be 25.96 pence during the second quarter.

  • The Quarterly Performance of GSK’s Vaccines Segment
    Market Realist11 days ago

    The Quarterly Performance of GSK’s Vaccines Segment

    GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, Shingles vaccines, and established vaccines. The segment reported a 7% rise in YoY (year-over-year) revenue to ~1.2 billion British pounds during the first quarter. This rise followed a 13% rise in operating revenue offset by the 6% negative impact of foreign exchange during the quarter.

  • PFE vs. GSK: Which Stock Is the Better Value Option?
    Zacks11 days ago

    PFE vs. GSK: Which Stock Is the Better Value Option?

    PFE vs. GSK: Which Stock Is the Better Value Option?

  • The Quarterly Performances of GlaxoSmithKline’s Business Segments
    Market Realist12 days ago

    The Quarterly Performances of GlaxoSmithKline’s Business Segments

    GlaxoSmithKline’s (GSK) product portfolio is separated into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline reported a rise in revenue at constant exchange rates across all three of its segments during the first quarter of 2018 compared to the first quarter of 2017. The Pharmaceuticals segment reported a 4% fall in YoY (year-over-year) revenue to ~4.0 billion British pounds during the first quarter, including a 2% rise in operating revenue offset by the 6% negative impact of foreign exchange.

  • GlaxoSmithKline’s Quarterly Revenue Trend and Estimates
    Market Realist12 days ago

    GlaxoSmithKline’s Quarterly Revenue Trend and Estimates

    GlaxoSmithKline (GSK) reported revenue of ~7.2 billion British pounds in the first quarter, a 2% fall compared to the ~7.3 billion pounds it reported during the first quarter of 2017. Its revenue included a 4% rise in operating revenue, which was more than offset by the 6% negative impact of foreign exchange during the quarter. GlaxoSmithKline reports its revenues under three business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.

  • GlaxoSmithKline’s Valuation on June 29
    Market Realist12 days ago

    GlaxoSmithKline’s Valuation on June 29

    GlaxoSmithKline (GSK) is a global pharmaceutical company with a focus on sustainable growth through strategizing its business beyond pharmaceuticals. GlaxoSmithKline reports its financial statements in British pounds.

  • Financial Times13 days ago

    [$$] GSK director sued over US opioid epidemic

    , the British pharmaceuticals company, has been sued by the state of Massachusetts for her alleged role in fuelling the US opioid addiction epidemic. Judy Lewent, who served on the board of opioid drugmaker Purdue Pharma for more than four years until 2014, was named as a defendant in a lawsuit filed by the state’s attorney-general last month.

  • 4 Drug and Biotech Stocks Awaiting FDA Decisions in July
    InvestorPlace13 days ago

    4 Drug and Biotech Stocks Awaiting FDA Decisions in July

    It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. Key FDA approvals in the first half included Amgen (NASDAQ:AMGN)/Novartis’s first CGRP antibody Aimovig/erenumab for prevention of migraine, Johnson & Johnson’s (NYSE:JNJ) next-generation oral androgen receptor (“AR”) inhibitor Erleada (apalutamide) for pre-metastatic prostate cancer (CRPC), Vertex Pharmaceuticals’ (NASDAQ:VRTX) third medicine to treat the underlying cause of CF, Symdeko, which is a combination of tezacaftor and ivacaftor and BioMarin Pharmaceuticals’ Palynziq to treat phenylketonuria (PKU). FDA Decision on Indivior’s Schizophrenia Injection RBP-7000: On Jul 28, the FDA is expected to give its decision on Indivior‘s (OTCMKTS:INVVY) RBP-7000, which has been developed for the treatment of schizophrenia.

  • Moody's13 days ago

    Novartis Securities Investment Ltd -- Moody's downgrades Novartis' rating to A1; stable outlook

    Moody's Investors Service has today downgraded to A1 from Aa3 the long-term ratings of Swiss multinational pharmaceutical maker Novartis AG (Novartis) and its guaranteed subsidiaries. The outlook on the ratings is stable.

  • New Strong Sell Stocks for July 2nd
    Zacks13 days ago

    New Strong Sell Stocks for July 2nd

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • 4 Drug and Biotech Stocks Awaiting FDA Decisions in July
    Zacks14 days ago

    4 Drug and Biotech Stocks Awaiting FDA Decisions in July

    In the first six months of the year, the FDA grants approval to 17 new treatments.

  • Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
    Zacks16 days ago

    Sanofi (SNY) Finalizes Deal for European Generic Unit Sale

    Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.

  • Investopedia16 days ago

    Interested In Pharmaceutical Stocks? Try Novartis (ADR)

    The pharmaceutical industry is the cornerstone of modern medicine in the modern capitalist world, and it is a key component to a well-diversified stock portfolio. The Novartis of today was created through a series of mergers and acquisitions, the most recent being AveXis ( AVXS) for $8.7 billion in April 2018. The company can trace its history back to the mid-18 th and 19 th centuries to two Swiss companies: CIBA, founded in 1859, and J.R. Geigy Ltd., founded in 1758.

  • Will a Trade War With China Wreak Havoc in US Healthcare?
    Zacks16 days ago

    Will a Trade War With China Wreak Havoc in US Healthcare?

    It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.

  • A Look at Eli Lilly’s Valuations on June 25
    Market Realist18 days ago

    A Look at Eli Lilly’s Valuations on June 25

    Eli Lilly (LLY) is one of the leading global drug manufacturers, and it operates under two segments—Human Pharmaceuticals and Animal Health Products. Eli Lilly surpassed Wall Street analysts’ estimates for earnings per share and revenues for the first quarter and reported EPS of $1.34 on revenues of $5.7 billion during the quarter.

  • 3 Dividend Stocks That Pay You More Than Verizon Does
    Motley Fool18 days ago

    3 Dividend Stocks That Pay You More Than Verizon Does

    Looking for companies that return big value to shareholders? Verizon checks that box, but these three stocks have it beat.

  • Should You Expect GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO) To Continue Delivering An ROE Of 17.05%?
    Simply Wall St.19 days ago

    Should You Expect GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO) To Continue Delivering An ROE Of 17.05%?

    This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO)’s returnRead More...

  • Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA
    Zacks19 days ago

    Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA

    Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.

  • ACCESSWIRE20 days ago

    Stock Performance Review on Pfizer and Three Other Drug Makers Stocks

    Stock Research Monitor: GSK, MRK, and NVS LONDON, UK / ACCESSWIRE / June 26, 2018 / If you want a free Stock Review on PFE sign up now at www.wallstequities.com/registration . On Monday, benchmark US indices ...